EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Changes in the use of glucose‐lowering drugs: A Danish nationwide study

Anton Pottegård iD, Jacob H Andersen iD, Jens Søndergaard iD, Reimar W Thomsen iD, Tina Vilsbøll iD

Diabetes, Obesity and Metabolism · 2023-04 · 25 (4) · 1002-1010

DOI: 10.1111/dom.14947 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 03.01.2023. Verfasst von Anton Pottegård und 4 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, Pharmacy, and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Dipeptidyl-Peptidase IV Inhibitors. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To investigate changes in the pattern of drugs used to treat type 2 diabetes in Denmark from 2005 to 2021. Materials and Methods A nationwide, population‐based drug utilization study based on medical databases covering the Danish population was conducted. We assessed incident and prevalent use patterns among all 441 205 individuals initiating at least one non‐insulin, glucose‐lowering drug.

Results

The rate of new users of non‐insulin, glucose‐lowering drugs increased from 2005, peaked in 2011, decreased to stable levels during 2013 to 2019, then increased dramatically during 2020‐2021. The prevalence of use increased from 2.1% (in 2005) to 5.0% (in 2021) of the entire adult population. In 2021, metformin comprised 39% of all glucose‐lowering drug consumption, followed by insulin (17%), sodium‐glucose co‐transporter‐2 inhibitors (SGLT‐2is) (17%), glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) (16%) and dipeptidyl peptidase‐4 inhibitors (7.5%). Overall, 56% of users were on monotherapy, 28% used dual therapy, while 13% and 2.8% used three and four drug classes, respectively. Both the intensity and diversity of therapies increased substantially over time, with 15 different treatment regimens each covering more than 1% of users in 2021. General practitioners prescribed 88% of all glucose‐lowering drugs. Marked shifts towards GLP‐1RA initiation by general practitioners and SGLT‐2i initiation by specialists were observed, and changing user profiles suggested increasing use for non‐diabetes indications.

Conclusions

The rate of new users of non‐insulin, glucose‐lowering drugs has increased in recent years and the prevalence of glucose‐lowering drug use increases steadily. Glucose‐lowering drugs are mainly prescribed by general practitioners, and the intensity, diversity and indications of glucose‐lowering treatment are increasing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsDipeptidyl-Peptidase IV InhibitorsAdultHumansHypoglycemic AgentsGlucoseInsulinInsulin, Regular, HumanDenmarkGlucagon-Like Peptide-1 Receptor Agonists

Stichwörter der Autor:innen

antidiabeticsdrug utilizationglucagon-like peptide-1 receptor agonistsglucose-lowering medicationpharmacoepidemiologysodium-glucose co-transporter-2 inhibitorstype 2 diabetes

Substanzen

Hypoglycemic AgentsGlucoseSodium-Glucose Transporter 2 InhibitorsDipeptidyl-Peptidase IV InhibitorsInsulinInsulin, Regular, HumanGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Clinical Pharmacology, Pharmacy, and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark.
  • Research Unit of General Practice, Department of Public Health, University of Southern Denmark, Odense, Denmark.
  • Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University Hospital and Aarhus University, Aarhus, Denmark.
  • Clinical Research, Steno Diabetes Center Copenhagen, Herlev, Denmark.
  • Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

ORCID-Profile: Anton Pottegård, Jacob H Andersen, Jens Søndergaard, Reimar W Thomsen, Tina Vilsbøll

Zitieren

APA

Pottegård, A., Andersen, J. H., Søndergaard, J., Thomsen, R. W., & Vilsbøll, T. (2023). Changes in the use of glucose‐lowering drugs: A Danish nationwide study. Diabetes, Obesity and Metabolism, 25(4), 1002-1010. https://doi.org/10.1111/dom.14947

Vancouver

Pottegård A, Andersen JH, Søndergaard J, Thomsen RW, Vilsbøll T. Changes in the use of glucose‐lowering drugs: A Danish nationwide study. Diabetes, Obesity and Metabolism. 2023;25(4):1002-1010. doi:10.1111/dom.14947

BibTeX
@article{Pottegrd2023,
  author = {Pottegård, Anton and Andersen, Jacob H and Søndergaard, Jens and Thomsen, Reimar W and Vilsbøll, Tina},
  title = {Changes in the use of glucose‐lowering drugs: A Danish nationwide study},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2023},
  volume = {25},
  number = {4},
  pages = {1002--1010},
  doi = {10.1111/dom.14947}
}
Kostenlos starten →